EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Engineered exosomes: a potential therapeutic strategy for septic cardiomyopathy

Lixia Mao, Songtao Liu, Yongxia Chen, Huiyi Huang, Fenghua Ding, Liehua Deng

Frontiers in Cardiovascular Medicine · 28.06.2024 · 11

DOI: 10.3389/fcvm.2024.1399738 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 28.06.2024. Verfasst von Lixia Mao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Critical Care Medicine, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Septic cardiomyopathy, a life-threatening complication of sepsis, can cause acute heart failure and carry a high mortality risk. Current treatments have limitations. Fortunately, engineered exosomes, created through bioengineering technology, may represent a potential new treatment method. These exosomes can both diagnose and treat septic cardiomyopathy, playing a crucial role in its development and progression. This article examines the strategies for using engineered exosomes to protect cardiac function and treat septic cardiomyopathy. It covers three innovative aspects: exosome surface modification technology, the use of exosomes as a multifunctional drug delivery platform, and plant exosome-like nanoparticle carriers. The article highlights the ability of exosomes to deliver small molecules, proteins, and drugs, summarizing several RNA molecules, proteins, and drugs beneficial for treating septic cardiomyopathy. Although engineered exosomes are a promising biotherapeutic carrier, they face challenges in clinical application, such as understanding the interaction mechanism with host cells, distribution within the body, metabolism, and long-term safety. Further research is essential, but engineered exosomes hold promise as an effective treatment for septic cardiomyopathy.

Schlagwörter

Stichwörter der Autor:innen

drug deliveryengineered exosomesextracellular vesiclessepsisseptic cardiomyopathy

Autor:innen und Institutionen

  • Department of Critical Care Medicine, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
  • Outpatient Appointment Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.

Zitieren

APA

Mao, L., Liu, S., Chen, Y., Huang, H., Ding, F., & Deng, L. (2024). Engineered exosomes: a potential therapeutic strategy for septic cardiomyopathy. Frontiers in Cardiovascular Medicine, 11. https://doi.org/10.3389/fcvm.2024.1399738

Vancouver

Mao L, Liu S, Chen Y, Huang H, Ding F, Deng L. Engineered exosomes: a potential therapeutic strategy for septic cardiomyopathy. Frontiers in Cardiovascular Medicine. 2024;11. doi:10.3389/fcvm.2024.1399738

BibTeX
@article{Mao2024,
  author = {Mao, Lixia and Liu, Songtao and Chen, Yongxia and Huang, Huiyi and Ding, Fenghua and Deng, Liehua},
  title = {Engineered exosomes: a potential therapeutic strategy for septic cardiomyopathy},
  journal = {Frontiers in Cardiovascular Medicine},
  year = {2024},
  volume = {11},
  doi = {10.3389/fcvm.2024.1399738}
}
Kostenlos starten →